Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes

Serruys, Patrick W; Onuma, Yoshinobu; Ormiston, John A; de Bruyne, Bernard; Regar, Evelyn; Dudek, Dariusz; Thuesen, Leif; Smits, Pieter C; Chevalier, Bernard; McClean, Dougal; Koolen, Jacques; Windecker, Stephan; Whitbourn, Robert; Meredith, Ian; Dorange, Cécile; Veldhof, Susan; Miquel-Hebert, Karine; Rapoza, Richard; García-García, Hector M (2010). Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes. Circulation, 122(22), pp. 2301-12. Baltimore, Md.: Lippincott Williams & Wilkins 10.1161/CIRCULATIONAHA.110.970772

Full text not available from this repository. (Request a copy)

The first generation of the bioresorbable everolimus drug-eluting vascular scaffold showed signs of shrinkage at 6 months, which largely contributed to late luminal loss. Nevertheless, late luminal loss was less than that observed with bare metal stents. To maintain the mechanical integrity of the device up to 6 months, the scaffold design and manufacturing process of its polymer were modified.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Cardiology

UniBE Contributor:

Windecker, Stephan

ISSN:

0009-7322

Publisher:

Lippincott Williams & Wilkins

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:10

Last Modified:

04 May 2014 23:05

Publisher DOI:

10.1161/CIRCULATIONAHA.110.970772

PubMed ID:

21098436

Web of Science ID:

000284691700018

URI:

https://boris.unibe.ch/id/eprint/1627 (FactScience: 203405)

Actions (login required)

Edit item Edit item
Provide Feedback